Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany

Infection

Volumn 27, Issue 1, 1999, Pages 23-27

  Dietrich, Eva Susanne ^a   Patz, E ^a   Frank, U ^a   Daschner, F D ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN; CILASTATIN PLUS IMIPENEM; IMIPENEM;

ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEVER; HUMAN; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CEFTAZIDIME; CEFTRIAXONE; CILASTATIN; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEVER; GERMANY; HUMANS; IMIPENEM; LONGITUDINAL STUDIES; NEOPLASMS; NETILMICIN; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 0032899897     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02565166     Document Type: Article

References (37)

1. 1. Hughes, W. T., Armstrong, D., Bodey, G. P., Feld, R., Mandell, L., Meyers, J. D., Pizzo, P. A., Schimpff, S. C., Shenep, J. L., Wade, J. D., Young, L. S., Yow, M. D. from the Infectious Diseases Society of America: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J. Infect. Dis. 161 (1990) 381-396.
2. 2. 1997 Drug Topics Red Book. Medical Economics Company, Inc., Montvale, 1997.
3. 3. Herbrecht, R., Blaise, D., Espinouse, D., Leblond, V., Sadoun, A., Sauvage, C., Cordonnier, C., Minozzi, C.: Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients. J. Chemother. 7 (Suppl. 2) (1995) 103-110.
4. 4. Liu, C. Y., Wang, F. D.: A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients. Chemotherapy 35 (Suppl. 2) (1989) 16-22.
5. 5. Yataganas, X., Rombos, Y., Vayopoulos, G., Meletis, J., Avlami, A.: Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients. Chemotherapy 37 (1991) 376-381.
6. 6. Au, E., Tow, A., Allen, D. M., Ang, P. T.: Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever. Ann. Acad. Med. Singapore 23 (1994) 819-822.
7. 7. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann. Intern. Med. 119 (1993) 584-593.
8. 8. Platzeck, C., König, H. J., Manger, B.: Effektivität verschiedener Doppel-Betalaktam- und Betalaktam/Aminoglykosid-Kombinationen bei der Initialtherapie neutropenischer Patienten mit Fieber. Zeitschrift für antimikrobielle antineoplastische Chemotherapic 10 (1992) 55-62.
9. 9. Aparicio, J., Oltra, A., Llorca, C., Montalar, J., Herranz, C., Gomez-Codina, J., Pastor, M., Munarriz, B.: Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur. J. Cancer 32A (1996) 1739-1743.
10. 10. De Pauw, B., Williams, K., de Neeff, J., Bothof, T., de Witte, T., Holdrinet, R., Haanen, C. A.: A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob. Agents Chemother. 28 (1985) 824-828.
11. 11. De Pauw, B. E., Deresinski, S. C., Feld, R., Lane-Allman, E. F., Donnelly, J. P.: Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann. Intern. Med. 120 (1994) 834-844.
12. 12. Donnelly, J. P., Marcus, R. E., Goldman, J. M., Cohen, J., Worsley, A. M., Catovsky, D., Darrell, J. H., Want, S. V., Galton, D. A. G.: Ceftazidime as first-line therapy for fever in acute leukaemia. J. Infect. 11 (1985) 205-215.
13. 13. Engervall, P., Gunther, G., Ljungman, P., Lönnqvist, B., Hast, R., Stiernstedt, G., Kalin, M., Ringertz, S., Bjölkholm, M.: Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. Scand. J. Infect. Dis. 28 (1996) 297-303.
14. 14. Freifeld, A. G., Walsh, T., Marshall, D., Gress, J., Steinberg, S. M., Hathorn, J., Rubin, M., Jarosinski, P., Gill, V., Young, R. C., Pizzo, P. A.: Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J. Clin. Oncol. 13 (1995) 165-176.
15. 15. Liang, R., Yung, R., Chiu, E., Chau, P. Y., Chan, T. K., Lam, W. K., Todd, D.: Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob. Agents Chemother. 34 (1990) 1336-1341.
16. 16. Novakova, I., Donnelly, P., De Pauw, B.: Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scand. J. Infect. Dis. 22 (1990) 705-711.
17. 17. Novakova, I., Donnelly, J. P., De Pauw, B.: Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob. Agents Chemother. 35 (1991) 672-678.
18. 18. Novakova, I., Donnelly, J. P., De Pauw, B.: Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients. Ann. Hematol. 63 (1991) 195-200.
19. 19. Pizzo, P. A., Hathorn, J. W., Hiemenz, J., Browne, M., Commern, J., Cotton, D., Gress, J., Longo, D., Marshall, D., McKnight, J., Rubin, M., Skelton, J., Thaler, M., Wesley, R.: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N. Engl. J. Med. 315 (1986) 552-558.
20. 20. Ramphal, R., Bolger, M., Oblon, D. J., Sherertz, R. J., Malone, J. D., Rand, K. H., Gilliom, M., Shands, J. W., Kramer, B. S.: Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob. Agents Chemother. 36 (1992) 1062-1067.
21. 21. Verhagen, C. S., de Pauw, B., de Witte, T., Janssen, J., Williams, K., de Mulder, P., Bothof, T.: Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob. Agents Chemother. 31 (1987) 191-196.
22. 22. Bayston, K. F., Want, S., Cohen, J.: A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever. Am. J. Med. 87 (1989) 269S-273S.
23. 23. De Pauw, B. E., Kauw, F., Muytjens, H., Wiliams, K. J., Bothof, T.: Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J. Antimicrob. Chemother. 12 (Suppl. A) (1983) 93-99.
24. 24. Fainstein, V., Bodey, G. P., Elting, L., Bolivar, R., Keating, M. J., McCredie, K. B., Valdivieso, M.: A randomized study of ceftazidime compared lo ceftazidime and tobramycin for the treatment of infections in cancer patients. J. Antimicrob. Chemother. 12 (Suppl. A) (1983) 101-110.
25. 25. Kramer, B. S., Ramphal, R., Rand, K. H.: Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob. Agents Chemother. 30 (1986) 64-68.
26. 26. Rolston, K. V., Berkey, P., Bodey, G. P., Anaissie, E. J., Khardori, N. M., Joshi, J. H., Keating, M. J., Holmes, F. A., Cabanillas, F. F., Elting, L.: A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch. Intern. Med. 152 (1992) 283-291.
27. 27. The Meropenem Study Group of Leuven, London and Nijmegen: Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J. Antimicrob. Chemother. 36 (1995) 185-200.
28. 28. Miller, J. A., Butler, T., Beveridge, R. A., Kales, A. N., Binder, R. A., Smith, L. J., Ueno, W. M., Milkovich, G., Goldwater, S., Marion, A., Eron, L., Mangi, R., Byrnes, C. A., Liss, C., Pashko, S.: Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. Clin. Ther. 15 (1993) 486-499.
29. 29. Mortimer, J., Miller, S., Black, D., Kwok, K., Kirby, M. K.: Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Am. J. Med. 85 (1988) 17-20.
30. 30. Mortimer, J. E., Black, D. W., Fijalka, S.: Comparison of cefoperazone and mezlocillin with imipenem/cilastatin in febrile neutropenic patients with cancer. Cur. Ther. Res. 49 (1991) 701-710.
31. 31. Cornelissen, J. J., de Graeff, A., Verdonck, L. F., Brander, T., Rozenberg-Arska, M., Verhoef, J., Dekker, A. W.: Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients. Antimicrob. Agents Chemother. 36 (1992) 801-807.
32. 32. Kojima, A., Shinkai, T., Soejima, Y., Okamoto, H., Eguchi, K., Sasaki, Y., Tamura, T., Oshita, F., Ohe, P., Saijo, N.: A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. Am. J. Clin. Oncol. 17 (1994) 400-404.
33. 33. Leyland, M. J., Bayston, K. F., Cohen, J., Warren, R., Newland, A. C., Bint, A. J., Cefai, C., White, D. G., Murray, S. A., Bareford, D., Deaney, N. B.: A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J. Antimicrob. Chemother. 30 (1992) 843-854.
34. 34. Matsui, K., Masuda, N., Takada, M., Kusunoki, Y., Fukuoka, M.: A randomized trial comparing imipenem/cilastatin alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn. J. Clin. Oncol. 21 (1991) 428-434.
35. 35. Winston, D. J., Ho, W. G., Bruckner, D. A., Champlin, R. E.: Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann. Intern. Med. 115 (1991) 849-859.
36. 36. Leese, B.: The costs of treating febrile neutropenia in six U.K. hospitals. Eur. J. Cancer 29 A (1993) S15-S18.
37. 37. Winston, D. J., Ho, W. G., Bruckner, D. A.: Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann. Intern. Med. 115 (1991) 849-859.